TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 29.93%256.9B | 29.62%164.39B | 26.95%75.51B | -3.24%270.97B | -7.60%197.73B | -11.63%126.83B | -18.91%59.48B | -14.70%280.04B | -11.84%214B | -12.84%143.52B |
Operating income | 29.93%256.9B | 29.62%164.39B | 26.95%75.51B | -3.24%270.97B | -7.60%197.73B | -11.63%126.83B | -18.91%59.48B | -14.70%280.04B | -11.84%214B | -12.84%143.52B |
Cost of sales | -30.11%-202.8B | -27.79%-129.17B | -22.54%-58.68B | 8.16%-213.49B | 12.34%-155.86B | 15.09%-101.08B | 21.04%-47.89B | 13.92%-232.47B | 10.71%-177.8B | 12.05%-119.04B |
Operating expenses | -30.11%-202.8B | -27.79%-129.17B | -22.54%-58.68B | 8.16%-213.49B | 12.34%-155.86B | 15.09%-101.08B | 21.04%-47.89B | 13.92%-232.47B | 10.71%-177.8B | 12.05%-119.04B |
Gross profit | 29.25%54.11B | 36.78%35.22B | 45.19%16.83B | 20.81%57.48B | 15.64%41.86B | 5.21%25.75B | -8.80%11.59B | -18.34%47.58B | -16.98%36.2B | -16.48%24.48B |
Selling expenses | -32.62%-17.66B | -32.63%-11.38B | -33.56%-5.48B | 9.83%-19.23B | 13.92%-13.32B | 18.96%-8.58B | 21.92%-4.1B | -1.63%-21.32B | -5.06%-15.47B | -7.56%-10.59B |
Administrative expenses | -13.10%-4.12B | -18.75%-2.71B | -34.17%-1.52B | -0.25%-5.13B | 4.50%-3.64B | 11.00%-2.28B | 8.79%-1.14B | -7.91%-5.11B | -11.80%-3.82B | -19.74%-2.56B |
Research and development expenses | -21.85%-16.61B | -22.95%-10.66B | -25.43%-5.16B | -19.15%-19.1B | -20.36%-13.63B | -19.43%-8.67B | -17.71%-4.11B | -21.73%-16.03B | -21.62%-11.33B | -19.45%-7.26B |
Revaluation surplus | -153.08%-1.53B | -165.33%-2.08B | -135.52%-1.23B | 310.65%3.5B | 153.02%2.88B | 204.64%3.18B | 197.27%3.45B | -120.44%-1.66B | -227.62%-5.43B | -148.75%-3.04B |
-Changes in the fair value of other assets | -153.08%-1.53B | -165.33%-2.08B | -135.52%-1.23B | 310.65%3.5B | 153.02%2.88B | 204.64%3.18B | 197.27%3.45B | -120.44%-1.66B | -227.62%-5.43B | -148.75%-3.04B |
Special items of operating profit | 77.22%1.43B | 116.89%1.17B | 17.07%243.25M | 491.95%2.48B | 215.72%807M | 352.43%537.83M | 375.36%207.78M | 57.14%-633.35M | -157.56%-697.36M | -115.18%-213.06M |
Operating profit | 4.42%15.61B | -3.71%9.57B | -37.58%3.68B | 610.41%20.01B | 2,872.75%14.95B | 1,109.68%9.94B | 747.48%5.9B | -89.18%2.82B | -102.49%-539.25M | -95.65%821.77M |
Financing income | 13.13%2.83B | 23.99%1.9B | 50.33%1.02B | 113.85%3.56B | 127.20%2.5B | 136.87%1.53B | 155.23%678.15M | 35.30%1.66B | 20.20%1.1B | 8.00%645.69M |
Financing cost | 124.27%276.51M | 141.55%433.69M | 146.94%519.91M | -184.72%-1.56B | -164.13%-1.14B | -612.23%-1.04B | -582.36%-1.11B | 80.77%-546.48M | 78.39%-431.36M | 80.08%-146.55M |
Earning before tax | 14.74%18.72B | 14.15%11.9B | -4.54%5.22B | 459.51%22.01B | 12,428.29%16.31B | 689.33%10.43B | 1,415.30%5.47B | -83.89%3.93B | -99.37%130.21M | -92.95%1.32B |
Tax | -16.08%-4.14B | -4.49%-2.66B | 16.37%-1.05B | -216.95%-4.54B | -363.12%-3.56B | -423.51%-2.54B | -994.51%-1.25B | 72.12%-1.43B | 79.16%-769.31M | 81.95%-486.09M |
After-tax profit from continuing operations | 14.37%14.58B | 17.27%9.24B | -1.02%4.17B | 598.25%17.47B | 2,095.11%12.75B | 844.11%7.88B | 894.67%4.22B | -87.02%2.5B | -103.79%-639.1M | -94.80%834.82M |
Earning after tax | 14.37%14.58B | 17.27%9.24B | -1.02%4.17B | 598.25%17.47B | 2,095.11%12.75B | 844.11%7.88B | 894.67%4.22B | -87.02%2.5B | -103.79%-639.1M | -94.80%834.82M |
Minority profit | -1,711.44%-49.29M | -573.78%-37.18M | -171.95%-8.85M | -103.42%-977K | -91.98%3.06M | -78.21%7.85M | -78.44%12.3M | 150.88%28.54M | 395.97%38.15M | 493.65%36.02M |
Profit attributable to shareholders | 14.79%14.63B | 17.86%9.28B | -0.52%4.18B | 606.34%17.48B | 1,982.27%12.75B | 885.71%7.87B | 815.43%4.2B | -87.21%2.47B | -104.02%-677.25M | -95.03%798.8M |
Basic earnings per share | 15.69%0.59 | 15.63%0.37 | 0.00%0.17 | 600.00%0.7 | 1,800.00%0.51 | 966.67%0.32 | 950.00%0.17 | -87.18%0.1 | -104.48%-0.03 | -95.31%0.03 |
Diluted earnings per share | 14.00%0.57 | 16.13%0.36 | -5.88%0.16 | 590.00%0.69 | 1,766.67%0.5 | 933.33%0.31 | 950.00%0.17 | -86.84%0.1 | -104.55%-0.03 | -95.24%0.03 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.